Insider Buying: ADARx Pharmaceuticals (NASDAQ:ADRX) Director Acquires $27,200,000.00 in Stock

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Director Simeon George acquired 1,600,000 shares of the business’s stock in a transaction on Monday, September 28th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the transaction, the director directly owned 5,554,094 shares of the company’s stock, valued at $94,419,598. This trade represents a 40.46% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

ADARx Pharmaceuticals Trading Up 2.7%

NASDAQ:ADRX traded up $0.55 during mid-day trading on Tuesday, hitting $20.64. The stock had a trading volume of 1,299,367 shares, compared to its average volume of 1,252,283. ADARx Pharmaceuticals, Inc. has a 52 week low of $18.50 and a 52 week high of $23.21.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing RNA-based medicines for immune-mediated and other serious diseases. The company is headquartered in San Diego, California, and uses proprietary technologies designed to modulate disease-related proteins at the RNA level.

ADARx’s pipeline includes investigational therapies intended to address conditions involving the complement system, coagulation pathways and other biologic mechanisms. Its programs are designed to provide targeted, durable treatment through approaches such as RNA interference and related forms of RNA-based therapeutic intervention.

Founded in 2018, ADARx has advanced its drug candidates through preclinical and clinical development and has pursued regulatory and clinical activities in the United States and other international markets.